In this study, we showed that combining the second-generation FLT3 inhibitor gilteritinib with the dual PI3K/HDAC inhibitor CUDC-907 synergistically improved anti-leukemic activity against FLT3-ITD acute myeloid leukemia (AML) – and that each agent reciprocally overcame resistance to the other drug.

In a proof-of-principle study published in Blood Cancer Journal, we showed that human CAR T cells can be generated within the host upon injecting an Adeno-associated virus (AAV) vector carrying the CAR gene, which we call AAV delivering CAR gene therapy (ACG).

Chimeric antigen receptor (CAR)-T cell therapy is a new treatment option for certain cancers whose use in clinical practice presents novel challenges and opportunities. Here we highlight a review outlining some limitations and potential strategies to overcome the limitations of CAR-T cell therapy.

Lenalidomide has moderate activity in relapsed or refractory diffuse large B-cell lymphoma. Its efficacy may be improved by combination with chemotherapy.

1 of the major un met need for patients with amyloidosis is earlier diagnosis. Currently 30% of patients succumb to the disease within the 1st year following diagnosis. This is because the diagnosis is delayed due to failure recognize.

One of the most common cytogenetic abnormalities in myeloma is one of the most widely debated and poorly understood. We have summarized the literature of this mysterious genomic aberration and call for standardization as a key to understanding the significance of +1q and improving patient outcomes.

My diagnosis was PMBCL; stage IV